RARE Ultragenyx Pharmaceutical Inc

Price (delayed)

$90.35

Market cap

$6.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.31

Enterprise value

$5.88B

Highlights
The revenue has surged by 125% year-on-year and by 8% since the previous quarter
The company's gross profit has surged by 124% YoY and by 7% QoQ
The quick ratio has soared by 80% YoY but it has decreased by 12% QoQ
The equity has increased by 40% year-on-year but it has declined by 8% since the previous quarter
Ultragenyx Pharmaceutical's net income has shrunk by 73% QoQ and by 17% YoY
RARE's EPS has dropped by 72% since the previous quarter

Key stats

What are the main financial stats of RARE
Market
Shares outstanding
67.84M
Market cap
$6.13B
Enterprise value
$5.88B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.27
Price to sales (P/S)
17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.37
Earnings
Revenue
$359.38M
EBIT
-$350.2M
EBITDA
-$337.49M
Free cash flow
-$411.33M
Per share
EPS
-$5.31
Free cash flow per share
-$6.08
Book value per share
$14.41
Revenue per share
$5.32
TBVPS
$19.78
Balance sheet
Total assets
$1.51B
Total liabilities
$540.27M
Debt
$46.17M
Equity
$972.17M
Working capital
$822.43M
Liquidity
Debt to equity
0.05
Current ratio
7.47
Quick ratio
6.85
Net debt/EBITDA
0.73
Margins
EBITDA margin
-93.9%
Gross margin
95.5%
Net margin
-97.8%
Operating margin
-93.6%
Efficiency
Return on assets
-22.9%
Return on equity
-36.5%
Return on invested capital
-41.4%
Return on capital employed
-25.3%
Return on sales
-97.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RARE stock price

How has the Ultragenyx Pharmaceutical stock price performed over time
Intraday
5.73%
1 week
12.45%
1 month
-4.1%
1 year
8.26%
YTD
-34.73%
QTD
-5.24%

Financial performance

How have Ultragenyx Pharmaceutical's revenue and profit performed over time
Revenue
$359.38M
Gross profit
$343.23M
Operating income
-$336.54M
Net income
-$351.43M
Gross margin
95.5%
Net margin
-97.8%
The revenue has surged by 125% year-on-year and by 8% since the previous quarter
The company's gross profit has surged by 124% YoY and by 7% QoQ
Ultragenyx Pharmaceutical's net income has shrunk by 73% QoQ and by 17% YoY
The company's operating margin has surged by 62% YoY

Growth

What is Ultragenyx Pharmaceutical's growth rate over time

Valuation

What is Ultragenyx Pharmaceutical stock price valuation
P/E
N/A
P/B
6.27
P/S
17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.37
RARE's EPS has dropped by 72% since the previous quarter
The equity has increased by 40% year-on-year but it has declined by 8% since the previous quarter
RARE's price to book (P/B) is 18% less than its last 4 quarters average of 7.2 but 10% more than its 5-year quarterly average of 5.4
The revenue has surged by 125% year-on-year and by 8% since the previous quarter
The P/S is 100% lower than the 5-year quarterly average of 4976.5 and 32% lower than the last 4 quarters average of 23.8

Efficiency

How efficient is Ultragenyx Pharmaceutical business performance
The return on assets has dropped by 67% since the previous quarter but it has increased by 13% year-on-year
RARE's return on sales has dropped by 61% since the previous quarter but it is up by 48% year-on-year
The ROE has dropped by 60% since the previous quarter but it is up by 19% year-on-year
The company's return on invested capital has shrunk by 55% QoQ but it rose by 23% YoY

Dividends

What is RARE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RARE.

Financial health

How did Ultragenyx Pharmaceutical financials performed over time
The total assets is 180% more than the total liabilities
The current ratio has soared by 81% YoY but it is down by 11% QoQ
The quick ratio has soared by 80% YoY but it has decreased by 12% QoQ
Ultragenyx Pharmaceutical's debt is 95% less than its equity
The equity has increased by 40% year-on-year but it has declined by 8% since the previous quarter
Ultragenyx Pharmaceutical's debt has increased by 27% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.